Ajantha Pharma gets USFDA approval for Zolmitripton Tablets

Ajanta Pharma on Tuesday announced the receipt of final approval for Zolmitripton Tablets by US  Food & Drug Administration. Zolmitripton is used in the acute treatment of migraine and is a bio equivalent generic version of Zomig®

The  Zolmitripton tablet is a part of a growing portfolio of products that Ajanta has developed specifically for US markets. The company has got 9  abbreviated new drug applications (ANDAs) final approvals so far and 2 tentative approvals with additional 15 ANDAs being under review with the FDA.

Ajanta Pharma closed down by 1.56 percent on Tuesday at  Rs.1464  even as broader markets were up by 0.30 percent at 25,305 levels.  BSE healthcare was down by 0.88 percent. The stock has delivered 3.54 percent over a 1 year period and over a 3 months period the stock has delivered 13 percent returns.  The stock is trading above its 200  day Simple Daily Moving Average (SDMA) indicating bullishness in the scrip.  The 52 w High for the stock is 1720 and the 52 w Low for the stock is at 1103.